Life Technologies works closely with industry leaders to improve the therapeutic pipeline and success rate of experiments and trials. Our technology provides the tools and services necessary to sequence genetic information to formulate vaccines and other treatments. We combine next-generation sequencing, in silico gene design and synthesis, synthetic biology products, and manufacturing capabilities to form a comprehensive synthetic vaccine development workflow.

The healthcare demands in developing and developed countries are wide-ranging and growing. Worldwide, the healthcare industry requires ways to streamline the drug research–development–application pipeline to make it more efficient and scalable, to deliver costeffective vaccines for infectious diseases and novel solutions for large, aging populations. This industry has the potential to treat, heal, and save millions of lives.

Solutions for Improved Vaccines

By accessing modern omics analysis techniques and precision molecular manipulation tools, the promise of significant health improvements and preventive strategies for all individuals is closer than ever. At Life Technologies, we’re partnering with the industry’s most forward-thinking leaders to improve the therapeutic pipeline and success rate of experiments and trials. Together, we’re employing innovative, rigorous, and robust tools to provide comprehensive solutions to the pharmaceuticals and biopharmaceuticals industries to better develop, optimize, and mass-produce the prophylactics and treatments needed.

Our End-to-End Solutions Support Your Goals to:

1. Develop vaccines

Enhanced and longer-lived immune responses

Improved efficacies and safety profiles

Immune responses that are more focused on relevant targets and epitopes

Proven Synthetic Vaccine Capabilities

Life Technologies has a proven track record for our GeneArt® molecular engineering tools in vaccine development. Below are a few examples of how our tools are fueling industry breakthroughs:

Successful testing of an engineered HIV vaccine

In February 2008, GeneArt was awarded two US patents to protect the use of specific, custom-designed HIV gene sequences for development of therapeutics or vaccines. In a 40-person clinical trial, the prophylactic vaccination proved to be safe and well tolerated, and it triggered a strong and lasting immune response in 90 % of the vaccinated subjects (J Exp Med 205:63 (2008)). Additional trials are ongoing. In 2009, GeneArt was awarded a contract by the HIV Vaccine Consortium (UK) to design and produce two HIV vaccine candidates based on the HIV gene sequences used in the 2008 trial.

Production of synthetic genes for the development of an H1N1 vaccine in 5 days

In May 2009, the GeneArt gene synthesis and assembly platform was employed to create synthetic H1N1 genes for a top European pharmaceutical company, and the product was delivered within a 5-day period. GeneArt created an additional ten H1N1 viral coat protein constructs for the Robert Koch Institute (the central federal institution responsible for disease control and prevention in Germany).

The proof is in the published

Our tools and technologies for synthetic biology have been widely cited, and have been featured in the Journal of Virology, the Journal of Immunology,Human Vaccines, and the Proceedings of the National Academy of Sciences of the United States of America, among several others. Research topics have included the implications of synthetic biology, vaccine development, and research breakthroughs related to HIV, Ebola viruses, and malaria.